Xadago 100 mg/1

Xadago 100 mg tablets contain safinamide mesylate, a medication used to manage symptoms of Parkinson's disease. This film-coated tablet is designed for oral use and is manufactured by MDD US Operations LLC, a subsidiary of Supernus Pharmaceuticals, Inc.

Xadago is primarily used as an add-on treatment for Parkinson's disease in patients who are already taking levodopa and carbidopa. Safinamide mesylate works by modulating dopamine levels in the brain, which can help alleviate symptoms such as tremors, stiffness, and difficulty moving. It is often prescribed to improve motor function and reduce fluctuations in symptoms.

Common effects of Xadago may include dizziness, nausea, and insomnia. Some users might experience hallucinations or uncontrolled movements. It is important to monitor for any unusual changes in behavior or physical symptoms while taking this medication.

Xadago should be used with caution in patients with a history of mental health issues, as it may increase the risk of hallucinations or other psychiatric symptoms. It is also important to avoid sudden discontinuation of the medication without consulting a healthcare provider. Patients with liver or kidney problems should discuss their condition with a healthcare professional before starting Xadago.

Xadago may interact with other medications that affect dopamine levels, such as other Parkinson's disease treatments. It is also important to be cautious when taking Xadago with medications that are metabolized by the liver, as safinamide mesylate can affect liver enzymes. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.